ducovest

TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 55

Change

0.00 (0.00)%

Market Cap

USD 2.01B

Volume

0.48M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

 USD 120.60B
REGN Regeneron Pharmaceuticals Inc

N/A

 USD 84.94B
ARGX argenx NV ADR

N/A

 USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD 31.66B
BGNE BeiGene Ltd

N/A

 USD 20.24B
UTHR United Therapeutics Corporatio..

N/A

 USD 16.18B
MRNA Moderna Inc

N/A

 USD 16.10B
RPRX Royalty Pharma Plc

N/A

 USD 15.05B
INCY Incyte Corporation

N/A

 USD 13.52B
SMMT Summit Therapeutics PLC

N/A

 USD 13.43B

ETFs Containing TARS

BASE:CA Evolve Global Materials &.. 5.71 % 0.00 %

N/A

 CAD 0.04B
BASE-B:CA Evolve Global Materials &.. 5.71 % 0.00 %

N/A

 CAD 0.08B
FXZ First Trust Materials Alp.. 5.18 % 0.64 %

N/A

 N/A
SLX VanEck Steel ETF 5.09 % 0.56 %

N/A

 N/A
XME SPDR® S&P Metals and Min.. 4.73 % 0.35 %

N/A

 N/A
XPH SPDR® S&P Pharmaceutical.. 3.47 % 0.35 %

N/A

 N/A
PJP Invesco Dynamic Pharmaceu.. 3.07 % 0.56 %

N/A

 N/A
SMLL Harbor ETF Trust 3.06 % 0.28 %

N/A

 N/A
BBP Virtus LifeSci Biotech Pr.. 1.73 % 0.79 %

N/A

 USD 0.02B
PICK iShares MSCI Global Metal.. 1.58 % 0.39 %

N/A

 USD 0.31B
IVOG Vanguard S&P Mid-Cap 400 .. 1.10 % 0.20 %

N/A

 USD 1.13B
IJK iShares S&P Mid-Cap 400 G.. 1.10 % 0.24 %

N/A

 USD 9.31B
IJJ iShares S&P Mid-Cap 400 V.. 1.02 % 0.25 %

N/A

 USD 8.33B
IWC iShares Micro-Cap ETF 0.47 % 0.60 %

N/A

 N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

 N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

N/A

 N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 171.60% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 171.60% 94% A 96% N/A
Trailing 12 Months  
Capital Gain 171.60% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 171.60% 94% A 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.15% 63% D 70% C-
Dividend Return 17.15% 63% D 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 65.22% 54% F 30% F
Risk Adjusted Return 26.29% 81% B- 58% F
Market Capitalization 2.01B 87% B+ 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector